---
figid: PMC7582884__41392_2020_340_Fig1_HTML
figtitle: PI3K/Akt signal pathway, p53 signal pathway, and mTOR signal pathway in
  NPC
organisms:
- Moloney murine leukemia virus
- Human gammaherpesvirus 4
- Adenoviridae
- Macacine gammaherpesvirus 4
- Canis lupus familiaris
- Equus caballus
- Felis catus
- herbal medicine
- Bikinia letestui
- Homo sapiens
- Mus musculus
- Caenorhabditis elegans
- NA
pmcid: PMC7582884
filename: 41392_2020_340_Fig1_HTML.jpg
figlink: pmc/articles/PMC7582884/figure/Fig1/
number: F1
caption: PI3K/Akt signal pathway, p53 signal pathway, and mTOR signal pathway in NPC.
  LMP1 latent membrane protein 1, LMP2A latent membrane protein 2A, PIP2 phosphatidylinositol
  4,5-bisphosphate, PIP3 phosphatidylinositol 3,4,5-trisphosphate, PTEN phosphatase,
  and tensin homolog, PI3K phosphoinositide 3-kinase, DNMT1 DNA methyltransferase
  1, SREBP1 sterol regulatory element-binding protein 1, VM vasculogenic mimicry,
  NaBu sodium butyrate, MK2 mitogen-activated protein kinase-activated protein kinase
  2, CCND1 cyclin D1, MYH9 myosin heavy chain 9, ITGB3 integrin β3, MDK midkine, FGF2
  fibroblast growth factor 2, COL1A1 collagen type I alpha 1, RBM3 RNA-binding motif
  protein 3, PNUTS phosphatase 1 nuclear-targeting subunit, CDKN3 cyclin-dependent
  kinase inhibitor 3, SQSTM1 Sequestosome-1, LZTS2 leucine zipper tumor suppressor
  2, UBQLN1 ubiquilin1, SMG1 suppressor of morphogenesis in genitalia 1, MDM2 murine
  double minute 2, COX-2 cycloxygenase-2, Bmi-1 B-cell-specific Moloney murine leukemia
  virus insertion site 1, EMT epithelial–mesenchymal transformation. Among them, LMP1,
  mTOR, PI3K, HIF-1α, miR-92a, Annexin A1, CDKN3, OCT4, c-Src, and COX-2 can be used
  as prognostic markers of NPC. The preclinical studies of NPC show that HIF-1α, COX-2
  has a good research value in targeted therapy. EGFR inhibitor, VEGF inhibitor, VEGFR
  inhibitor, and Akt inhibitor show positive effects and have less and tolerable adverse
  reactions in phase II clinical trials of NPC
papertitle: Advances in targeted therapy mainly based on signal pathways for nasopharyngeal
  carcinoma.
reftext: Yuanbo Kang, et al. Signal Transduct Target Ther. 2020;5:245.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9719765
figid_alias: PMC7582884__F1
figtype: Figure
organisms_ner:
- Equus caballus
- Canis lupus familiaris
- Homo sapiens
- Mus musculus
- Felis catus
- Caenorhabditis elegans
redirect_from: /figures/PMC7582884__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7582884__41392_2020_340_Fig1_HTML.html
  '@type': Dataset
  description: PI3K/Akt signal pathway, p53 signal pathway, and mTOR signal pathway
    in NPC. LMP1 latent membrane protein 1, LMP2A latent membrane protein 2A, PIP2
    phosphatidylinositol 4,5-bisphosphate, PIP3 phosphatidylinositol 3,4,5-trisphosphate,
    PTEN phosphatase, and tensin homolog, PI3K phosphoinositide 3-kinase, DNMT1 DNA
    methyltransferase 1, SREBP1 sterol regulatory element-binding protein 1, VM vasculogenic
    mimicry, NaBu sodium butyrate, MK2 mitogen-activated protein kinase-activated
    protein kinase 2, CCND1 cyclin D1, MYH9 myosin heavy chain 9, ITGB3 integrin β3,
    MDK midkine, FGF2 fibroblast growth factor 2, COL1A1 collagen type I alpha 1,
    RBM3 RNA-binding motif protein 3, PNUTS phosphatase 1 nuclear-targeting subunit,
    CDKN3 cyclin-dependent kinase inhibitor 3, SQSTM1 Sequestosome-1, LZTS2 leucine
    zipper tumor suppressor 2, UBQLN1 ubiquilin1, SMG1 suppressor of morphogenesis
    in genitalia 1, MDM2 murine double minute 2, COX-2 cycloxygenase-2, Bmi-1 B-cell-specific
    Moloney murine leukemia virus insertion site 1, EMT epithelial–mesenchymal transformation.
    Among them, LMP1, mTOR, PI3K, HIF-1α, miR-92a, Annexin A1, CDKN3, OCT4, c-Src,
    and COX-2 can be used as prognostic markers of NPC. The preclinical studies of
    NPC show that HIF-1α, COX-2 has a good research value in targeted therapy. EGFR
    inhibitor, VEGF inhibitor, VEGFR inhibitor, and Akt inhibitor show positive effects
    and have less and tolerable adverse reactions in phase II clinical trials of NPC
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - EGFR
  - TP53
  - MDM2
  - CDKN3
  - DNMT1
  - MIR18A
  - MIR125A
  - PTGS2
  - LZTS2
  - MIR92A
  - PTEN
  - MIR125B
  - UBQLN1
  - MIR155
  - FOXO1
  - MYH9
  - FGF2
  - MIR16-1
  - MYC
  - MDK
  - SNAI1
  - SQSTM1
  - BCL2
  - MIR29A
  - COL1A1
  - MIR374A
  - JUN
  - SRC
  - RBM3
  - CCND1
  - MTOR
  - HIF1A
  - SMG1
  - CDKN1A
  - SREBF1
  - TP63
  - TP73
  - ADRA1D
  - PDLIM7
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PPP1R10
  - TCEAL1
  - NSG1
  - H3P16
  - FGF13
  - GDE1
  - AKT1
  - AKT2
  - AKT3
  - MMDK
  - KCNA2
  - MAPKAPK2
  - MIR1275
  - FAM225A
  - Egf
  - Egfr
  - Trp53
  - Mdm2
  - Cdkn3
  - Dnmt1
  - Mir18
  - Mir125a
  - Spaca6
  - Ptgs2
  - Lzts2
  - Pten
  - Pik3r1
  - Ppp1r10
  - Ubqln1
  - Mir155
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - Foxo1
  - Myh9
  - Fgf2
  - Mir16-1
  - Myc
  - Nol3
  - Akt1
  - Mdk
  - Snai1
  - Sqstm1
  - Bcl2
  - Mir29a
  - Col1a1
  - Jun
  - Src
  - Rbm3
  - Ccnd1
  - Kcna2
  - Mapkapk2
  - Map2k2
  - Mtor
  - Hif1a
  - Srebf1
  - Smg1
  - Prt4
  - COX2
  - lmp-1
  - snai-1
  - smg-1
  - NaBu
---
